<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p123" style="overflow: hidden; position: relative; background-color: white; width: 935px; height: 1210px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_123{left:119px;bottom:1134px;letter-spacing:0.11px;word-spacing:0.02px;}
#t2_123{left:799px;bottom:1132px;letter-spacing:-0.08px;}
#t3_123{left:162px;bottom:1085px;letter-spacing:0.12px;word-spacing:3.23px;}
#t4_123{left:162px;bottom:1067px;letter-spacing:0.11px;word-spacing:0.02px;}
#t5_123{left:162px;bottom:1050px;letter-spacing:0.11px;word-spacing:3.17px;}
#t6_123{left:162px;bottom:1032px;letter-spacing:0.11px;word-spacing:1.24px;}
#t7_123{left:162px;bottom:1015px;letter-spacing:0.1px;word-spacing:-0.21px;}
#t8_123{left:162px;bottom:997px;letter-spacing:0.11px;word-spacing:0.03px;}
#t9_123{left:162px;bottom:979px;letter-spacing:0.13px;}
#ta_123{left:300px;bottom:979px;letter-spacing:0.12px;word-spacing:2.43px;}
#tb_123{left:162px;bottom:962px;letter-spacing:0.11px;word-spacing:0.3px;}
#tc_123{left:162px;bottom:944px;letter-spacing:0.1px;word-spacing:0.02px;}
#td_123{left:141px;bottom:884px;letter-spacing:0.14px;}
#te_123{left:162px;bottom:850px;letter-spacing:0.13px;word-spacing:0.03px;}
#tf_123{left:238px;bottom:850px;letter-spacing:0.11px;word-spacing:0.03px;}
#tg_123{left:162px;bottom:832px;letter-spacing:0.11px;word-spacing:0.52px;}
#th_123{left:162px;bottom:814px;letter-spacing:0.1px;word-spacing:0.03px;}
#ti_123{left:162px;bottom:779px;letter-spacing:0.12px;}
#tj_123{left:256px;bottom:779px;letter-spacing:0.12px;word-spacing:4.04px;}
#tk_123{left:162px;bottom:762px;letter-spacing:0.11px;word-spacing:-0.44px;}
#tl_123{left:162px;bottom:744px;letter-spacing:0.11px;word-spacing:-0.19px;}
#tm_123{left:162px;bottom:726px;letter-spacing:0.1px;word-spacing:0.02px;}
#tn_123{left:162px;bottom:709px;letter-spacing:0.12px;word-spacing:1.76px;}
#to_123{left:328px;bottom:709px;letter-spacing:0.11px;word-spacing:1.75px;}
#tp_123{left:162px;bottom:691px;letter-spacing:0.11px;word-spacing:2.14px;}
#tq_123{left:162px;bottom:674px;letter-spacing:0.1px;word-spacing:0.02px;}
#tr_123{left:162px;bottom:656px;letter-spacing:0.1px;}
#ts_123{left:222px;bottom:656px;letter-spacing:0.12px;word-spacing:2.94px;}
#tt_123{left:162px;bottom:639px;letter-spacing:0.1px;word-spacing:1.17px;}
#tu_123{left:364px;bottom:639px;letter-spacing:0.11px;word-spacing:1.18px;}
#tv_123{left:162px;bottom:621px;letter-spacing:0.1px;word-spacing:0.02px;}
#tw_123{left:162px;bottom:604px;letter-spacing:0.11px;}
#tx_123{left:245px;bottom:604px;letter-spacing:0.11px;word-spacing:0.45px;}
#ty_123{left:162px;bottom:586px;letter-spacing:0.12px;word-spacing:1.82px;}
#tz_123{left:162px;bottom:568px;letter-spacing:0.11px;word-spacing:0.64px;}
#t10_123{left:162px;bottom:551px;letter-spacing:0.12px;word-spacing:3.05px;}
#t11_123{left:162px;bottom:533px;letter-spacing:0.1px;word-spacing:0.01px;}
#t12_123{left:162px;bottom:516px;letter-spacing:0.13px;}
#t13_123{left:292px;bottom:516px;letter-spacing:0.11px;word-spacing:0.12px;}
#t14_123{left:162px;bottom:498px;letter-spacing:0.11px;word-spacing:0.03px;}
#t15_123{left:141px;bottom:441px;letter-spacing:0.15px;word-spacing:-0.01px;}
#t16_123{left:162px;bottom:420px;letter-spacing:0.14px;word-spacing:-0.15px;}
#t17_123{left:162px;bottom:380px;letter-spacing:0.13px;word-spacing:0.04px;}
#t18_123{left:268px;bottom:393px;letter-spacing:-0.02px;}
#t19_123{left:276px;bottom:393px;}
#t1a_123{left:281px;bottom:380px;letter-spacing:0.12px;word-spacing:0.03px;}
#t1b_123{left:389px;bottom:393px;letter-spacing:-0.03px;}
#t1c_123{left:404px;bottom:380px;letter-spacing:0.11px;word-spacing:0.03px;}
#t1d_123{left:492px;bottom:393px;letter-spacing:-0.03px;}
#t1e_123{left:507px;bottom:380px;letter-spacing:0.11px;word-spacing:0.02px;}
#t1f_123{left:593px;bottom:393px;}
#t1g_123{left:598px;bottom:380px;letter-spacing:0.12px;word-spacing:0.03px;}
#t1h_123{left:697px;bottom:393px;}
#t1i_123{left:162px;bottom:370px;}
#t1j_123{left:167px;bottom:356px;letter-spacing:0.08px;word-spacing:-0.83px;}
#t1k_123{left:437px;bottom:370px;}
#t1l_123{left:442px;bottom:356px;letter-spacing:0.11px;word-spacing:-0.83px;}
#t1m_123{left:162px;bottom:332px;letter-spacing:0.11px;word-spacing:4.76px;}
#t1n_123{left:404px;bottom:346px;}
#t1o_123{left:409px;bottom:332px;letter-spacing:0.13px;word-spacing:4.45px;}
#t1p_123{left:162px;bottom:315px;letter-spacing:0.1px;word-spacing:-0.26px;}
#t1q_123{left:372px;bottom:323px;}
#t1r_123{left:377px;bottom:315px;letter-spacing:0.11px;word-spacing:-0.4px;}
#t1s_123{left:162px;bottom:279px;letter-spacing:0.11px;word-spacing:0.6px;}
#t1t_123{left:162px;bottom:262px;letter-spacing:0.11px;word-spacing:1.53px;}
#t1u_123{left:162px;bottom:244px;letter-spacing:0.1px;word-spacing:-0.17px;}
#t1v_123{left:162px;bottom:227px;letter-spacing:0.11px;word-spacing:1.95px;}
#t1w_123{left:162px;bottom:209px;letter-spacing:0.11px;word-spacing:-0.6px;}
#t1x_123{left:162px;bottom:191px;letter-spacing:0.11px;word-spacing:0.91px;}
#t1y_123{left:162px;bottom:174px;letter-spacing:0.12px;word-spacing:4.08px;}
#t1z_123{left:162px;bottom:157px;letter-spacing:0.1px;word-spacing:5.15px;}
#t20_123{left:162px;bottom:139px;letter-spacing:0.13px;word-spacing:4.75px;}
#t21_123{left:162px;bottom:121px;letter-spacing:0.11px;word-spacing:0.2px;}
#t22_123{left:162px;bottom:104px;letter-spacing:0.11px;word-spacing:0.77px;}
#t23_123{left:162px;bottom:86px;letter-spacing:0.11px;word-spacing:-0.54px;}

.s0_123{font-size:15px;font-family:TimesNewRomanPSMT_6e;color:#000;}
.s1_123{font-size:17px;font-family:Calibri_7k;color:#000;}
.s2_123{font-size:15px;font-family:TimesNewRomanPS-BoldMT_7s;color:#000;}
.s3_123{font-size:18px;font-family:TimesNewRomanPS-BoldMT_7w;color:#000;}
.s4_123{font-size:10px;font-family:TimesNewRomanPS-BoldMT_8j;color:#000;}
.s5_123{font-size:10px;font-family:TimesNewRomanPSMT_87;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts123" type="text/css" >

@font-face {
	font-family: Calibri_7k;
	src: url("fonts/Calibri_7k.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPS-BoldMT_7s;
	src: url("fonts/TimesNewRomanPS-BoldMT_7s.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPS-BoldMT_7w;
	src: url("fonts/TimesNewRomanPS-BoldMT_7w.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPS-BoldMT_8j;
	src: url("fonts/TimesNewRomanPS-BoldMT_8j.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPSMT_6e;
	src: url("fonts/TimesNewRomanPSMT_6e.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPSMT_87;
	src: url("fonts/TimesNewRomanPSMT_87.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg123Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg123" style="-webkit-user-select: none;"><object width="935" height="1210" data="123/123.svg" type="image/svg+xml" id="pdf123" style="width:935px; height:1210px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_123" class="t s0_123">Brain: Chemistry to Cognition </span><span id="t2_123" class="t s1_123">115 </span>
<span id="t3_123" class="t s0_123">burn injury which was attenuated by the atomoxetine treatment and the nitrite level was found to be </span>
<span id="t4_123" class="t s0_123">significantly reduced by the atomoxetine treatment. </span>
<span id="t5_123" class="t s0_123">Results indicate that Atomoxetine (StratteraÂ®), a selective norepinephrine (NE) reuptake inhibitor and </span>
<span id="t6_123" class="t s0_123">potential NMDA blocker, may be able to treat burn injury-induced chronic pain by significantly reducing </span>
<span id="t7_123" class="t s0_123">thermal hyperalgesia, mechanical allodynia, and the effects of potentially noxious or innocuous cold stimuli. </span>
<span id="t8_123" class="t s0_123">Hence, may show antinociceptive effects. </span>
<span id="t9_123" class="t s2_123">Acknowledgements: </span><span id="ta_123" class="t s0_123">We acknowledge the Department of Pharmaceutical Engineering and Technology, </span>
<span id="tb_123" class="t s0_123">Indian Institute of Technology, Banaras Hindu University, Varanasi, Uttar Pradesh, India, for providing the </span>
<span id="tc_123" class="t s0_123">necessary facilities and infrastructure. </span>
<span id="td_123" class="t s3_123">P60: Microglia extracellular traps: In health and disease </span>
<span id="te_123" class="t s2_123">Lipika Sha </span><span id="tf_123" class="t s0_123">and Sushmita Jha </span>
<span id="tg_123" class="t s0_123">Department of Bioscience and Bioengineering, Indian Institute of Technology Jodhpur, Jodhpur, Rajasthan </span>
<span id="th_123" class="t s0_123">- 342037 </span>
<span id="ti_123" class="t s2_123">Background: </span><span id="tj_123" class="t s0_123">Extracellular Traps (ETs) are extracellular web-like structures composed of nuclear or </span>
<span id="tk_123" class="t s0_123">mitochondrial DNA. ETs are released from various immune cells in response to different stimuli. Circulating </span>
<span id="tl_123" class="t s0_123">ETs can be markers of cancer. Our group discovered dopamine-induced microglia ETs. Our work confirmed </span>
<span id="tm_123" class="t s0_123">the presence of ETs in glioblastoma tissue. </span>
<span id="tn_123" class="t s2_123">Materials and Methods: </span><span id="to_123" class="t s0_123">Microglia cells (BV2) were stimulated with dopamine, cellular, molecular and </span>
<span id="tp_123" class="t s0_123">transcriptomic techniques to assess the structure and function, revealed key differences from Neutrophil </span>
<span id="tq_123" class="t s0_123">Extracellular traps. </span>
<span id="tr_123" class="t s2_123">Results: </span><span id="ts_123" class="t s0_123">Dopamine induces extracellular traps in microglia. Additionally, Dopamine induces microglia </span>
<span id="tt_123" class="t s0_123">glioblastoma cell proliferation. </span><span id="tu_123" class="t s0_123">Cellular, molecular and transcriptomic techniques reveal differences from </span>
<span id="tv_123" class="t s0_123">neutrophil extracellular traps. </span>
<span id="tw_123" class="t s2_123">Conclusion: </span><span id="tx_123" class="t s0_123">In the GBM microenvironment, tumour cells secrete and respond to dopamine in an autocrine </span>
<span id="ty_123" class="t s0_123">mechanism. Different cells in the GBM microenvironment, such as astrocytes and tumour cells, respond </span>
<span id="tz_123" class="t s0_123">differently to dopamine. The role of dopamine-induced microglia Extracellular Traps (miETs) in the GBM </span>
<span id="t10_123" class="t s0_123">microenvironment plays a vital role in GBM pathophysiology, this may be investigated as a potential </span>
<span id="t11_123" class="t s0_123">therapeutic intervention. </span>
<span id="t12_123" class="t s2_123">Acknowledgement: </span><span id="t13_123" class="t s0_123">We are thankful to IIT Jodhpur for infrastructure, administrative and financial support. </span>
<span id="t14_123" class="t s0_123">Lipika Sha is supported by MoE (Ministry of Education) fellowship from IIT Jodhpur. </span>
<span id="t15_123" class="t s3_123">P61: Understanding the role of biased and unbiased KOR agonist in modulation of </span>
<span id="t16_123" class="t s3_123">affective behaviour </span>
<span id="t17_123" class="t s2_123">Manish K. Dash </span>
<span id="t18_123" class="t s4_123">1,</span><span id="t19_123" class="t s5_123">3 </span>
<span id="t1a_123" class="t s0_123">, Poonam Kumari </span>
<span id="t1b_123" class="t s5_123">1, 4 </span>
<span id="t1c_123" class="t s0_123">, Lalan Kumar </span>
<span id="t1d_123" class="t s5_123">2, 4 </span>
<span id="t1e_123" class="t s0_123">, Sanjay Batra </span>
<span id="t1f_123" class="t s5_123">2 </span>
<span id="t1g_123" class="t s0_123">, Prem N.Yadav </span>
<span id="t1h_123" class="t s5_123">1 </span>
<span id="t1i_123" class="t s5_123">1 </span>
<span id="t1j_123" class="t s0_123">Neuroscience and Ageing Biology Division, </span>
<span id="t1k_123" class="t s5_123">1 </span>
<span id="t1l_123" class="t s0_123">Medicinal and Process ChemistryDivision, CSIR-Central Drug </span>
<span id="t1m_123" class="t s0_123">Research Institute, Lucknow, India; </span>
<span id="t1n_123" class="t s5_123">3 </span>
<span id="t1o_123" class="t s0_123">Academy of Scientific and Innovative Research (CSIR-HRDC) </span>
<span id="t1p_123" class="t s0_123">Ghaziabad, Uttar Pradesh (India); </span>
<span id="t1q_123" class="t s5_123">4 </span>
<span id="t1r_123" class="t s0_123">Jawaharlal Nehru University, New Delhi, 110067 </span>
<span id="t1s_123" class="t s0_123">Biased Kappa Opioid Receptor (KOR) agonists have emerged as promising candidates for the treatment of </span>
<span id="t1t_123" class="t s0_123">chronic pain conditions. Neuropathic pain is a highly unmet medical need as the available analgesics are </span>
<span id="t1u_123" class="t s0_123">either very moderately effective or mired with serious adverse effect profiles. Furthermore, neuropathic pain </span>
<span id="t1v_123" class="t s0_123">is highly associated with severe debilitating mood impairments, such as depression, anxiety, and loss of </span>
<span id="t1w_123" class="t s0_123">motivation. Although KOR agonist has been shown to attenuate nociceptive pain, role of biased KOR agonist </span>
<span id="t1x_123" class="t s0_123">on affective components of neuropathicpain is not known. Therefore, we evaluated the effect of G-protein </span>
<span id="t1y_123" class="t s0_123">biased and unbiased KOR agonist on neuropathic pain using Chronic Constriction Injury (CCI) and </span>
<span id="t1z_123" class="t s0_123">Chemotherapy-induced peripheral neuropathic pain (CIPN) models in SD rats and C57BL/6J mice, </span>
<span id="t20_123" class="t s0_123">respectively. We observed that following biased KOR agonist CDRI4/105 (10mg/kg; p.o., 7 days), </span>
<span id="t21_123" class="t s0_123">significantly alleviated hyperalgesia and allodyniain CCI and CIPN model of neuropathic pain. Conversely, </span>
<span id="t22_123" class="t s0_123">unbiased KOR agonist U50488 (5mg/kg; i.p.) didn't elevate paw withdrawal threshold significantly. These </span>
<span id="t23_123" class="t s0_123">results highlight CDRI4/105's potential therapeutic use in chronic pain conditions. Furthermore, we observed </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
